New therapy for advanced disease plus insight into the lives of those affected
Vienna (OTS) – Parkinson’s disease, the fastest growing neurological disease in the world, presents patients and their families with major challenges. In Austria, 20,000 to 30,000 people are currently affected – many of whom do not receive optimal therapeutic care – as a current survey by the opinion research institute Integral together with AbbVie shows.
Invitation to the press breakfast
If: January 23, 2024, 10 a.m. to probably 11:30 a.m
Wo: Press club Concordia, Bankgasse 8, 1010 Vienna
Set-up: hybrid; Your physical well-being will be taken care of on site.
Dial-in details will be sent if required.
As part of the press conference, experts will provide information about
- a new therapy for advanced Parkinson’s disease
- Detailed results of the patient and relative survey about life with Parkinson’s disease
- Opportunities for a better quality of life for patients
Interlocutors:
- Dr.in Stephanie Hirschbichler MSc, PhD, senior physician in the Department of Neurology at the University Hospital St. Pölten, head of the movement disorders clinic
- Dr.in Michaela Steffelbauerneurologist and president of Parkinson’s Self-Help Upper Austria
- Dr.in Andrea MaierMedical Director AbbVie Austria
We look forward to your participation and ask that you register in advance.
Best regards
Mag.a Gerlinde Baldauf
AbbVie Austria
PK Morbus Parkinson, 23.1.24
Datum: January 23, 2024, 10:00 a.m. – 11:30 a.m
Ort: Press Club Concordia
Bankgasse 8, 1010 Vienna, Austria
Url: https://hennrich-pr.at/de/termine/pk-parkinson-am-231/
Registration for the Parkinson press breakfast
Questions & Contact:
AbbVie GmbH
Mag.a Gerlinde Baldauf, MAS
Communications and Patient Relations Manager
+43 1 20589-279
gerlinde.soon@abbvie.com
www.abbvie.at
Hennrich PR GmbH
Daniela Hennrich Management
+ 43 664 408 18 18
d. henrich@hennrich-pr.at
www.hennrich-pr.at